1,076 results
Page 4 of 54
6-K
EX-99.1
hfonpqp4sg
24 Apr 23
Current report (foreign)
9:55am
6-K
EX-99.1
qj5 kgwtalj36l
11 Apr 23
Current report (foreign)
1:02pm
SC TO-T/A
EX-99
189k7v8ih1qyef hx
10 Apr 23
Third party tender offer statement (amended)
4:38pm
S-8
62am8bfnocut2xfuyws
30 Mar 23
Registration of securities for employees
1:36pm
6-K
EX-99.3
yn5qnfzr9mj
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.1
n543c1os
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.2
9fvgkjd9b
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.1
trlsu8su kjw3
2 Dec 22
Positive Phase II/III study results support acoziborole’s potential in treatment for deadly disease
10:40am
6-K
EX-99.1
zvwvy
21 Nov 22
European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
10:05am
6-K
EX-99.1
oabh9klblso2rm
15 Nov 22
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
3:01pm
6-K
EX-99.2
aaggk aqj
15 Nov 22
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
3:01pm
6-K
EX-99.1
ipj hzitlg1
10 Nov 22
European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
2:00pm
6-K
EX-99.1
jm1mt1 aip4
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.1
xjmh432u q4s
17 Oct 22
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
1:35pm
6-K
EX-99.1
dbmngp
3 Oct 22
Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
11:24am
6-K
EX-99.1
yzws 5y6hnx1zj
22 Sep 22
CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
9:49am
6-K
EX-99.2
6r6l62imctcv
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.3
qe3eljann
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.1
jiajwns
2 Sep 22
Current report (foreign)
9:44am
6-K
EX-99.2
59gc0rl21v mjcnpv
2 Sep 22
Current report (foreign)
9:44am